AN ACT concerning industrial hemp; establishing a commercial industrial
hemp program; amending K.S.A. 65-4101, 65-4105 and K.S.A. 2018
Supp. 2-3901, 2-3902, 2-3903, 21-5701 and 21-5702 and repealing the
existing sections; also repealing K.S.A. 65-4101c and 65-4105b and

Be it enacted by the Legislature of the State of Kansas:

New Section 1. (a) It is the intent of the legislature of the state of
Kansas that the implementation of the commercial industrial hemp act by
the Kansas department of agriculture shall be conducted in the least
restrictive manner allowed under federal law.
(b) This section shall be a part of and supplemental to the commercial
industrial hemp act, K.S.A. 2018 Supp. 2-3901 et seq., and amendments
thereto.

New Sec. 2. (a) The Kansas department of agriculture, in consultation
with the governor and attorney general, shall submit a plan to the United
States department of agriculture under which the Kansas department of
agriculture will monitor and regulate the commercial production of
industrial hemp within the state in accordance with 7 U.S.C. § 1621 et seq.
and any rules and regulations adopted thereunder.
(b) Such plan shall include the following:
(1) A procedure to maintain relevant information regarding land on
which industrial hemp is produced, including a legal description of the
land, for a period of not less than three calendar years;
(2) a procedure for testing, using post-decarboxylation or other
similarly reliable methods, the delta-9 tetrahydrocannabinol concentration
levels of industrial hemp produced;
(3) a procedure for the effective disposal of industrial hemp and hemp
products that are found to be in violation of this act;
(4) any licensing requirements or other rules and regulations deemed
necessary by the Kansas department of agriculture for the proper
monitoring and regulation of industrial hemp cultivation and production
for commercial purposes, including, but not limited to, fees for licenses,
license renewals and other necessary expenses to defray the cost of
implementing and operating the plan on an ongoing basis;
(5) a procedure for the creation of documentation that any person in
possession of unprocessed industrial hemp may use to prove to any law
enforcement officer that such industrial hemp was lawfully grown under
this section;
   (6) a procedure for conducting annual inspections of, at a minimum, a
random sample of hemp producers to verify that hemp is not produced in
violation of this act; and
   (7) any other procedures necessary to meet the requirements set forth
in 7 U.S.C. § 1621 et seq. and any rules and regulations adopted
thereunder.
(c) (1) A hemp producer who negligently violates this section or any
rules and regulations adopted thereunder shall not be subject to any state
or local criminal enforcement action, but shall comply with the following
corrective actions as applicable:
   (A) A reasonable date by which the hemp producer shall correct the
negligent violation; and
   (B) a requirement that the hemp producer shall periodically report to
the Kansas department of agriculture on the hemp producer's compliance
with this section and rules and regulations adopted thereunder, for a period
of not less than the next two calendar years.
   (2) A hemp producer who negligently violates this section or any
rules and regulations adopted thereunder three times in a five-year period
shall be ineligible to produce industrial hemp for a period of five years
beginning on the date of the third violation.
   (3) The Kansas department of agriculture shall immediately report
any violation by a hemp producer with a greater culpable mental state than
negligence to the attorney general and such hemp producer shall not be
subject to the exemption in subsection (c)(1).
(d) Any individual otherwise eligible to become a licensed hemp
producer shall not be eligible to produce industrial hemp if such individual
has submitted any materially false information in any application to
become a licensed hemp producer.
   (e) (1) The department shall require, as a qualification for initial or
continuing licensure, all individuals seeking a license or license renewal as
a hemp producer under this section to be fingerprinted and to submit to a
state and national criminal history record check. The fingerprints shall be
used to identify the individual and to determine whether the individual has
a record of criminal history in this state or any other jurisdiction. The
department is authorized to submit the fingerprints to the Kansas bureau of
investigation and the federal bureau of investigation for a state and
national criminal history record check. The department may use the
information obtained from fingerprinting and the criminal history record
check for purposes of verifying the identification of the individual and for
making an official determination of the qualifications for initial or
continuing licensure as a hemp producer pursuant to this section and rules and regulations promulgated hereunder. Disclosure or use of any information received by the department for any purpose other than the purposes provided for in the commercial industrial hemp act shall be a class A misdemeanor and shall constitute grounds for removal from office or termination of employment.

(2) An individual who has been convicted of a felony violation of article 57 of chapter 21 of the Kansas Statutes Annotated, and amendments thereto, or a substantially similar offense in another jurisdiction, within the immediately preceding 10 years, shall be disqualified from initial or continuing licensure as a hemp producer under this section.

(3) The Kansas bureau of investigation may charge a reasonable fee for conducting a criminal history record check.

(4) The individual seeking a license or license renewal as a hemp producer under this section shall pay the costs of fingerprinting and the state and national criminal history record checks.

(f) The secretary of agriculture shall promulgate rules and regulations to implement the plan submitted to the United States department of agriculture and to otherwise effectuate the provisions of this section.

(g) Upon the repeal of 7 U.S.C. § 5940 or either the adoption of a federal plan by the United States department of agriculture that allows for the cultivation and production of industrial hemp for commercial purposes within the state or upon the adoption of rules and regulations by the Kansas secretary of agriculture that establish the cultivation and production of industrial hemp for commercial purposes within the state, the Kansas department of agriculture may discontinue the industrial hemp research program established pursuant to K.S.A. 2018 Supp. 2-3902, and amendments thereto.

(h) Any modification fee established by the department for any requested change to a license that was previously issued by the department under this section shall not exceed $50.

(i) Any licensing or other fees collected pursuant to this section and any rules and regulations adopted hereunder shall be deposited in the commercial industrial hemp act licensing fee fund established by K.S.A. 2018 Supp. 2-3903, and amendments thereto, for all costs of the administration of the commercial production of industrial hemp.

(j) This section shall be a part of and supplemental to the commercial industrial hemp act, K.S.A. 2018 Supp. 2-3901 et seq., and amendments thereto.

New Sec. 3. The secretary of agriculture shall continue to accept any applications for licensure submitted under the provisions of K.S.A. 2018 Supp. 2-3902, and amendments thereto, for the 2019 growing season from March 1, 2019, through June 1, 2019.
New Sec. 4. (a) (1) There is hereby established the industrial hemp regulatory commission within the Kansas department of revenue. The industrial hemp regulatory commission shall be administered under the direction of a director of the industrial hemp regulatory commission, who shall be appointed by and serve at the pleasure of the secretary of revenue. The director shall be in the unclassified service under the Kansas civil service act and shall receive an annual salary fixed by the secretary of revenue and approved by the governor.

(2) The director of the industrial hemp regulatory commission shall be responsible for all powers, duties and functions assigned to the department of revenue under the commercial industrial hemp act.

(3) The industrial hemp regulatory commission shall adopt rules and regulations as necessary to implement and administer the provisions of the commercial industrial hemp act relating to the licensure and regulation of hemp processors and may advise and consult with the department of health and environment and the Kansas department of agriculture on such rules and regulations.

(4) The provisions of this section and any rules and regulations promulgated thereunder shall apply to any individual licensed by the Kansas department of agriculture to process, manufacture or distribute industrial hemp under the research program established by K.S.A. 2018 Supp. 2-3902, and amendments thereto, except that no such individual shall be subject to the licensure application or renewal fees set forth in this section.

(b) (1) The industrial hemp regulatory commission shall establish an electronic database to store information detailing:

(A) Each license issued to any hemp processor in accordance with this section, including any modification, revocation, suspension or other action relating to the license;

(B) each individual working as an employee, agent or unpaid worker of a hemp processor; and

(C) other information deemed necessary or appropriate by the director of the industrial hemp regulatory commission.

(2) Information in the database shall be shared with law enforcement authorities in a manner prescribed by the Kansas bureau of investigation for the purpose of verifying the validity of any identification card or license issued in accordance with the commercial industrial hemp act or the location of any operations authorized by the commercial industrial hemp act.

(c) (1) A person may apply to the industrial hemp regulatory commission for initial or renewed licensure as a hemp processor on a form, in a manner and accompanied by a licensure fee not to exceed $5,000 prescribed by the industrial hemp regulatory commission.
Licensure as a hemp processor shall authorize the licensee to process
industrial hemp into hemp products in accordance with and for the
purposes set forth in this section, and to perform other acts deemed
necessary and incidental thereto by the industrial hemp regulatory
commission, as established in rules and regulations adopted by the
industrial hemp regulatory commission.

(2) No person not in current compliance with any Kansas tax law
administered by the director of taxation of the department of revenue, any
tax, fee or payment administered by the department of labor or any fee or
charge administered by any other state agency shall have an ownership
interest in a hemp processor.

(3) An applicant shall provide the following information and
documentation on an application for licensure as a hemp processor:

(A) The name, address and telephone number of the applicant;

(B) the physical location of any premises that will be operated as a
part of the hemp processor's operations;

(C) documentation that the applicant is a resident of the state of
Kansas;

(D) the name of each owner of any land, structure or building where
any operations of the hemp processor will occur or any motor vehicle that
will be used to distribute or transport industrial hemp or hemp products
and each individual who will otherwise be involved with the hemp
processor's operations, whether as an employee or agent; and

(E) any other information required by the industrial hemp regulatory
commission.

(4) (A) The industrial hemp regulatory commission shall require any
individual working as an employee, agent or unpaid worker of a hemp
processor to be fingerprinted and to submit to a state and national criminal
history record check. The fingerprints shall be used to identify the
individual and to determine whether the individual has a record of criminal
history in this state or any other jurisdiction. The commission is authorized
to submit the fingerprints to the Kansas bureau of investigation and the
federal bureau of investigation for a state and national criminal history
record check. The commission may use the information obtained from
fingerprinting and the criminal history record check for purposes of
verifying the identification of the individual and for making an official
determination of the qualifications and fitness of the person to work as an
employee, agent or unpaid worker of the hemp processor. Disclosure or
use of any information received by the commission for any purpose other
than the purposes provided for in the commercial industrial hemp act shall
be a class A misdemeanor and shall constitute grounds for removal from
office or termination of employment.

(B) As a condition of licensure as a hemp processor under this-
section, an individual who has been convicted of a felony violation of article 57 of chapter 21 of the Kansas Statutes Annotated, and amendments thereto, or a substantially similar offense in another jurisdiction, within the immediately preceding 10 years, shall be disqualified from being employed, serving as an agent or otherwise working in any manner under a hemp processor under this section.

(C) The Kansas bureau of investigation may charge a reasonable fee for conducting a criminal history record check.

(D) The individual seeking to work as an employee, agent or unpaid worker of a hemp processor shall pay the costs of fingerprinting and the state and national criminal history record checks.

(5) Within 60 calendar days of receiving any application pursuant to this section, the industrial hemp regulatory commission shall issue a decision to grant or deny licensure to the applicant as a hemp processor.

(6) If the industrial hemp regulatory commission denies initial or renewed licensure to a hemp processor, the industrial hemp regulatory commission shall refund 1/2 of the applicant's application fee or renewal fee.

(7) (A) Licensure as a hemp processor shall be effective for a period of two years. If the industrial hemp regulatory commission grants initial or renewed licensure to a hemp processor, the industrial hemp regulatory commission shall require the applicant or licensee to:

(i) Pay a licensure fee not to exceed $5,000; and

(ii) provide satisfactory evidence that the hemp processor has obtained a surety bond in an amount required by the industrial hemp regulatory commission based on the size and actual and projected yield of the hemp processor operations, the number of facilities operated by the hemp processor and other factors established by the industrial hemp regulatory commission in rules and regulations.

(B) The industrial hemp regulatory commission shall remit all moneys from any fees under this section to the state treasurer in accordance with K.S.A. 75-4215, and amendments thereto. Upon receipt of each such remittance, the state treasurer shall deposit the entire amount of moneys into the state treasury to the credit of the commercial industrial hemp processor fund established by this section.

(8) The industrial hemp regulatory commission shall require any individual working as an employee, agent or unpaid worker of a hemp processor to have documentation in their possession at all times that they are engaged in the processing, manufacturing or distribution of industrial hemp or hemp products that would prove to any law enforcement officer that such individual is authorized to engage in such activities.

(9) All actions by the industrial regulatory commission under
this subsection shall be in accordance with the Kansas administrative
procedure act and reviewable in accordance with the Kansas judicial
review act.
(d) It shall be unlawful for a person to process, manufacture or
distribute industrial hemp or hemp products in violation of the provisions
of this section.
(1) Upon a first conviction for a violation of subsection (d), a person
shall be guilty of a class A nonperson misdemeanor and sentenced to not
more than one year in confinement and fined not less than $1,000, nor
more than $2,500.
(2) On a second conviction for a violation of subsection (d), a person
shall be guilty of a severity level 9, nonperson felony and fined a sum of
not less than $10,000, nor more than $100,000, and sentenced according to
the provisions of K.S.A. 21-6804, and amendments thereto.
(3) On a third or subsequent conviction for a violation of subsection
(d), a person shall be guilty of a severity level 9, nonperson felony and
fined a sum of not less than $50,000, nor more than $100,000, and
sentenced according to the provisions of K.S.A. 21-6804, and amendments
thereto.
(4) The penalties provided hereunder are cumulative to the remedies
or penalties, including all civil penalties, under all other laws of this state.
(e) There is hereby established in the state treasury the commercial
industrial hemp processor fund. The commercial industrial hemp processor
fund shall be administered by the industrial hemp regulatory commission.
All expenditures from the commercial industrial hemp processor fund shall
be used for costs related to hemp processor regulation and enforcement by
the industrial hemp regulatory commission. All expenditures from the
commercial industrial hemp processor fund shall be made in accordance
with appropriation acts upon warrants of the director of accounts and
reports issued pursuant to vouchers approved by the director of the
industrial hemp regulatory commission or the director's designee. All
moneys received by the director of the industrial hemp regulatory
commission from fees imposed by this section shall be deposited in the
state treasury in accordance with the provisions of K.S.A. 75-4215, and
amendments thereto, and shall be credited to the commercial industrial
hemp processor fund.
(f) This section shall be a part of and supplemental to the commercial
industrial hemp act, K.S.A. 2018 Supp. 2-3901 et seq., and amendments
thereto.
New Sec. 5. (a) (1) It shall be unlawful for any of the following hemp
products to be manufactured, marketed, sold or distributed by any person
in the state of Kansas:
(A) Cigarettes containing industrial hemp;
(B) cigars containing industrial hemp;
(C) chew, dip or other smokeless material containing industrial hemp;
(D) teas containing industrial hemp;
(E) liquids, solids or gases containing industrial hemp for use in vaporizing devices; and
(F) any hemp product intended for human or animal consumption containing any ingredient derived from industrial hemp, unless any such ingredient is generally recognized as safe under its intended conditions of use or otherwise approved by the United States food and drug administration under the federal drug and cosmetic act.

(2) As used in this subsection:
(A) "Human or animal consumption" means:
   (i) Ingested orally; or
   (ii) applied by any means such that an ingredient derived from industrial hemp enters the human or animal body.
(B) "Intended for human or animal consumption" means:
   (i) Designed by the manufacturer for human or animal consumption;
   (ii) marketed for human or animal consumption; or
   (iii) distributed with the intent that it be used for human or animal consumption.

(b) It shall be unlawful for any of the following hemp products to be marketed, sold or distributed to any person in Kansas who is not operating under a hemp processor license pursuant to this section, or who does not possess a license by the Kansas department of agriculture under any commercial plan established pursuant to section 2, and amendments thereto, or the research program established pursuant to K.S.A. 2018 Supp. 2-3902, and amendments thereto:

(1) Industrial hemp buds;
(2) ground industrial hemp floral material; and
(3) ground industrial hemp leaf material.

(c)(1) Upon a first conviction for a violation of this section, a person shall be guilty of a class A nonperson misdemeanor and sentenced to no more than one year in confinement and fined not less than $1,000, nor more than $2,500.
(2) On a second conviction for a violation of this section, a person shall be guilty of a severity level 9, nonperson felony and fined a sum of not less than $10,000, nor more than $100,000, and sentenced according to the provisions of K.S.A. 21-6804, and amendments thereto.
(3) On a third or subsequent conviction for a violation of this section, a person shall be guilty of a severity level 9, nonperson felony and fined a sum of not less than $50,000, nor more than $100,000, and sentenced according to the provisions of K.S.A. 21-6804, and amendments thereto.
(4) The penalties provided hereunder are cumulative to the remedies...
or penalties, including all civil penalties, under all other laws of this state.

(d) *(Nothing in this section shall prohibit:)*

(1) *The use of any hemp product for research purposes by a state educational institution or affiliated entity; or*

(2) *the production, use or sale of any hemp product that is otherwise authorized by state or federal law.*

(e) This section shall be a part of and supplemental to the commercial industrial hemp act, K.S.A. 2018 Supp. 2-3901 et seq., and amendments thereto.

New Sec. 6. (a) (1) All solid waste, as defined in K.S.A. 65-3402, and amendments thereto, and all hazardous waste, as defined in K.S.A. 65-3430, and amendments thereto, resulting from the cultivation, production or processing of industrial hemp under the commercial industrial hemp act shall be managed in accordance with all applicable solid and hazardous waste laws and regulations and the requirements of subsection (a)(2).

(2) (A) If any such waste can be used in the same manner as, or has the appearance of, a controlled substance, as defined in K.S.A. 65-4101, and amendments thereto, all such waste shall be rendered unusable and unrecognizable before the waste is transported or disposed.

(B) This requirement shall not apply to waste that is managed as a hazardous waste and sent to a hazardous waste facility, as defined in K.S.A. 65-3430, and amendments thereto.

(3) For the purposes of this act, "unusable and unrecognizable" means that such waste can not be used in the same manner as, and does not have the appearance of, a controlled substance, as defined in K.S.A. 65-4101, and amendments thereto.

(b) This section shall be a part of and supplemental to the commercial industrial hemp act, K.S.A. 2018 Supp. 2-3901 et seq., and amendments thereto.

Sec. 7. K.S.A. 2018 Supp. 2-3901 is hereby amended to read as follows: 2-3901. (a) K.S.A. 2018 Supp. 2-3901 and 2-3902 et seq., and amendments thereto, shall be known and may be cited as the *alternative crop research commercial industrial hemp act.*

(b) As used in the *alternative crop research commercial industrial hemp act:*

(1) "Certified seed" means industrial hemp seed that has been certified by a certifying agency, as defined by K.S.A. 2-1415, and amendments thereto, as having a delta-9 tetrahydrocannabinol concentration of no more than 0.3% on a dry weight basis.

(2) "Commercial" means the cultivation or production of industrial hemp for purposes other than research as authorized under section 2, and amendments thereto.

(2) "Delta-9 tetrahydrocannabinol concentration" means the
combined percentage of delta-9 tetrahydrocannabinol and its optical isomers, their salts and acids, and salts of their acids, reported as free THC on a dry weight basis, of any part of the plant cannabis sativa L.

(3) "Department" means the Kansas department of agriculture.

(4) "Effective disposal" includes, but is not limited to:

(A) Destruction; or

(B) any other method of disposing of industrial hemp or hemp products found to be in violation of this act that is permitted under the provisions of 7 U.S.C. § 1621 et seq. and any rules and regulations adopted thereunder.

(4) "Hemp products" means all products made from industrial hemp, including, but not limited to, cloth, cordage, fiber, food, fuel, paint, paper, particleboard, plastics, seed, seed meal and seed oil for consumption and certified authorized seed or clone plants for cultivation, if the seeds originate from industrial hemp varieties.

(5) "Hemp producer" means any individual, licensed or otherwise, engaging in the cultivation or production of industrial hemp for commercial purposes pursuant to section 2, and amendments thereto.

(5) "Hemp processor" means a person licensed under section 4, and amendments thereto, to process, manufacture and distribute industrial hemp and hemp products.

(7) "Industrial hemp" means all parts and varieties of the plant cannabis sativa L., cultivated or possessed by a state educational institution or the department, whether growing or not, that contain a delta-9 tetrahydrocannabinol concentration of not more than 0.3% on a dry weight basis.

(6) "Person" means an individual, corporation, partnership, association, joint stock company, trust, unincorporated organization or any similar entity or any combination of the foregoing acting in concert.

(9) "Seed research" means research conducted to develop or recreate better strains of industrial hemp, particularly for the purpose of seed production.

(7) "State educational institution" means the university of Kansas, Kansas state university, Wichita state university, Emporia state university, Pittsburg state university and Fort Hays state university.

(11) "Authorized seed or clone plants" means a source of industrial hemp seeds or clone plants that:

(A) Has been certified by a certifying agency, as defined by K.S.A. 2-1415, and amendments thereto;

(B) has been produced from plants that were tested during the active growing season and were found to produce industrial hemp having a tetrahydrocannabinol concentration that does not exceed 0.3% on a dry weight basis and has been certified in writing by the grower or distributor
of that such seeds or clone plants possess such qualities; or  
(C) meets any other authorized standards approved by the Kansas department of agriculture through rules and regulations, except that no seed or clone plants shall be considered authorized seed or clone plants if it does not meet any standard adopted by the United States department of agriculture pursuant to 7 U.S.C. § 1621 et seq.

Sec. 8. On and after July 1, 2019, K.S.A. 2018 Supp. 2-3902 is hereby amended to read as follows: 2-3902. (a) The Kansas department of agriculture, alone or in coordination with a state educational institution, may cultivate industrial hemp grown from certified authorized seed or clone plants and promote the research and development of industrial hemp, in accordance with 7 U.S.C. § 5940. This research may include:

(1) Oversight and analysis of growth of industrial hemp to conduct agronomy research and analysis of required soils, growing conditions and harvest methods relating to the production of various varieties of industrial hemp that may be suitable for various commercial hemp products;

(2) seed research on various types of industrial hemp that are best suited to be grown in Kansas, including seed availability, creation of hybrid types, in-the-ground variety trials and seed production;

(3) analysis on the economic feasibility of developing an industrial hemp market in various types of industrial hemp that can be grown in Kansas;

(4) analysis on the estimated value-added benefits, including environmental benefits, that Kansas businesses would reap by having an industrial hemp market of Kansas-grown industrial hemp varieties;

(5) a study on the agronomy research conducted worldwide relating to industrial hemp varieties, production and utilization;

(6) a study on the feasibility of attracting federal and private funding for industrial hemp research; and

(7) a pilot program in Russell county, and other counties as determined by the department, for the purpose of economic development, research, cultivation, market analysis, manufacturing and transportation of industrial hemp and industrial hemp products.

(b) In the event that the department acts alone to cultivate industrial hemp grown from certified authorized seed or clone plants and to promote the research and development of industrial hemp, the secretary of agriculture shall establish an advisory board within the department to review and recommend applications for pilot projects and research proposals to the secretary. The secretary shall not approve any such project or proposal without the recommendation of the advisory board.

(c) The department shall oversee and annually license all individuals participating in the cultivation, growth, research, oversight, study, analysis,
transportation, processing or distribution of certified authorized seed or clone plants or industrial hemp pursuant to this act section. The department shall establish fees for licenses, license renewals and other necessary expenses to defray the cost of implementing and operating the alternative crop research act provisions of this section in this state on an ongoing basis. Any modification fee established by the department for any requested change to a license that was previously issued by the department under this section shall not exceed $50.

(d)(1) The department shall require, as a qualification for initial or continuing licensure, all individuals seeking a license or license renewal under this act to be fingerprinted and to submit to a state and national criminal history record check. The fingerprints shall be used to identify the individual and to determine whether the individual has a record of criminal history in this state or any other jurisdiction. The department is authorized to submit the fingerprints to the Kansas bureau of investigation and the federal bureau of investigation for a state and national criminal history record check. The department may use the information obtained from fingerprinting and the criminal history record check for purposes of verifying the identification of the individual and for making an official determination of the qualifications for initial or continuing licensure pursuant to this act and rules and regulations promulgated pursuant to this act. Disclosure or use of any information received by the department for any purpose other than the purpose provided for in this section shall be a class A misdemeanor and shall constitute grounds for removal from office or termination of employment.

(2) An individual who has been convicted of any of the following shall be disqualified from initial or continuing licensure under this act: A felony violation of article 57 of chapter 21 of the Kansas Statutes Annotated, and amendments thereto, K.S.A. 2010 Supp. 21-36a01 through 21-36a17, prior to their transfer, or any felony violation of any provision of the uniform controlled substances act, prior to July 1, 2009.

(3) The Kansas bureau of investigation may charge a reasonable fee for conducting a criminal history record check.

(4) The applicant shall pay the costs of fingerprinting and the state and national criminal history record check.

(e)(1) The department shall require, as a qualification for initial or continuing licensure, all individuals seeking a license or license renewal under the research program established under this section to be fingerprinted and to submit to a state and national criminal history record check. The fingerprints shall be used to identify the individual and to determine whether the individual has a record of criminal history in this state or any other jurisdiction. The department is authorized to submit the fingerprints to the Kansas bureau of investigation and the federal bureau
of investigation for a state and national criminal history record check. The
department may use the information obtained from fingerprinting and the
criminal history record check for purposes of verifying the identification of
the individual and for making an official determination of the
qualifications for initial or continuing licensure pursuant to this section
and rules and regulations promulgated thereunder. Disclosure or use of
any information received by the department for any purpose other than the
purposes provided for in this section shall be a class A misdemeanor and
shall constitute grounds for removal from office or termination of
employment.

(2) An individual who has been convicted of a felony violation of
article 57 of chapter 21 of the Kansas Statutes Annotated, and
amendments thereto, or a substantially similar offense in another
jurisdiction, within the immediately preceding 10 years, shall be
disqualified from initial or continuing licensure under this section.

(3) The Kansas bureau of investigation may charge a reasonable fee
for conducting a criminal history record check.

(4) The individual seeking a license or license renewal under this
section shall pay the costs of fingerprinting and the state and national
criminal history record checks.

(e) The secretary of agriculture shall promulgate rules and regulations
to carry out the provisions of the alternative crop research act on or before December 31, 2018; except that no such promulgated
rule or regulation shall concern the recording of license plates. Such rules
and regulations shall include, but not be limited to, a requirement that
license holders shall have a current license in their possession at all times
that they are engaged in the cultivation, growth, research, oversight, study,
analysis, transportation, processing or distribution of authorized seed or
clon plants or industrial hemp pursuant to this section. Such rules and
regulations shall include, but not be limited to, a requirement that license
holders shall have a current license in their possession at all times that they
are engaged in cultivation, growth, research, oversight, study, analysis,
transportation, processing or distribution of certified seed or industrial
hemp pursuant to this act.

(f) The department shall submit a report to the legislature outlining
the steps and timeline to implement a process that would allow individuals
and business entities to grow and process industrial hemp in Kansas and to
sell industrial hemp in other states. Such report shall be submitted to the
senate standing committee on agriculture and natural resources and the
house standing committee on agriculture on or before January 14, 2019.
The department shall send such committees an annual supplemental report
on the continued progress of such process at the beginning of each regular
legislative session for the following three years.
(g) Nothing in the alternative crop research act this section shall be construed to authorize any individual to violate any state or federal law.

(h) The legislature shall review the provisions of this act section prior to July 1, 2022.

Sec. 9. K.S.A. 2018 Supp. 2-3903 is hereby amended to read as follows: 2-3903. (a) There is hereby created in the state treasury The alternative crop research act licensing fee fund created in the state treasury shall be renamed the commercial industrial hemp act licensing fee fund and continue to be administered by the secretary of agriculture. All expenditures from the alternative crop research commercial industrial hemp act licensing fee fund shall be made in accordance with appropriation acts upon warrants of the director of accounts and reports issued pursuant to vouchers signed by the secretary of agriculture or the secretary's designee.

(b) Licensing and renewal fees shall be established pursuant to rules and regulations adopted by the secretary under the alternative crop research commercial industrial hemp act. The amounts received for such fees shall be deposited in the state treasury in accordance with K.S.A. 75-4215, and amendments thereto, and shall be credited to the alternative crop research commercial industrial hemp act licensing fee fund.

Sec. 10. K.S.A. 2018 Supp. 21-5701 is hereby amended to read as follows: 21-5701. As used in K.S.A. 2018 Supp. 21-5701 through 21-5717, and amendments thereto: (a) "Controlled substance" means any drug, substance or immediate precursor included in any of the schedules designated in K.S.A. 65-4105, 65-4107, 65-4109, 65-4111 and 65-4113, and amendments thereto.

(b) (1) "Controlled substance analog" means a substance that is intended for human consumption, and at least one of the following:

(A) The chemical structure of the substance is substantially similar to the chemical structure of a controlled substance listed in or added to the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto;

(B) the substance has a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto; or

(C) with respect to a particular individual, such individual represents or intends the substance to have a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto.
"Controlled substance analog" does not include:

(A) A controlled substance;
(B) a substance for which there is an approved new drug application;
(C) a substance with respect to which an exemption is in effect for investigational use by a particular person under section 505 of the federal food, drug, and cosmetic act, 21 U.S.C. § 355, to the extent conduct with respect to the substance is permitted by the exemption.

"Cultivate" means the planting or promotion of growth of five or more plants which contain or can produce controlled substances.

"Distribute" means the actual, constructive or attempted transfer from one person to another of some item whether or not there is an agency relationship. "Distribute" includes, but is not limited to, sale, offer for sale or any act that causes some item to be transferred from one person to another. "Distribute" does not include acts of administering, dispensing or prescribing a controlled substance as authorized by the pharmacy act of the state of Kansas, the uniform controlled substances act or otherwise authorized by law.

"Drug" means:

(1) Substances recognized as drugs in the official United States pharmacopeia, official homeopathic pharmacopoeia of the United States or official national formulary or any supplement to any of them;

(2) substances intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in humans or animals;

(3) substances, other than food, intended to affect the structure or any function of the body of humans or animals; and

(4) substances intended for use as a component of any article specified in paragraph (1), (2) or (3). It does not include devices or their components, parts or accessories.

"Drug paraphernalia" means all equipment and materials of any kind— which are used, or primarily intended or designed for use in planting, propagating, cultivating, growing, harvesting, manufacturing, compounding, converting, producing, processing, preparing, testing, analyzing, packaging, repackaging, storing, containing, concealing, injecting, ingesting, inhaling or otherwise introducing into the human body a controlled substance and in violation of this act. "Drug paraphernalia" shall include, but is not limited to:

(1) Kits used or intended for use in planting, propagating, cultivating, growing or harvesting any species of plant— which is a controlled substance or from which a controlled substance can be derived;

(2) kits used or intended for use in manufacturing, compounding, converting, producing, processing or preparing controlled substances;

(3) isomerization devices used or intended for use in increasing the
potency of any species of plant that is a controlled substance;
(4) testing equipment used or intended for use in identifying or in
analyzing the strength, effectiveness or purity of controlled substances;
(5) scales and balances used or intended for use in weighing or
measuring controlled substances;
(6) diluents and adulterants, including, but not limited to, quinine
hydrochloride, mannitol, mannite, dextrose and lactose—which are
used or intended for use in cutting controlled substances;
(7) separation gins and sifters used or intended for use in removing
twigs and seeds from or otherwise cleaning or refining marijuana;
(8) blenders, bowls, containers, spoons and mixing devices used or
intended for use in compounding controlled substances;
(9) capsules, balloons, envelopes, bags and other containers used or
intended for use in packaging small quantities of controlled substances;
(10) containers and other objects used or intended for use in storing
or concealing controlled substances;
(11) hypodermic syringes, needles and other objects used or intended
for use in parenterally injecting controlled substances into the human
body;
(12) objects used or primarily intended or designed for use in
ingesting, inhaling or otherwise introducing marijuana, cocaine, hashish,
hashish oil, phencyclidine (PCP), methamphetamine or amphetamine into
the human body, such as:
   (A) Metal, wooden, acrylic, glass, stone, plastic or ceramic pipes with
or without screens, permanent screens, hashish heads or punctured metal
bowls;
   (B) water pipes, bongs or smoking pipes designed to draw smoke
through water or another cooling device;
   (C) carburetion pipes, glass or other heat resistant tubes or any other
device used, intended to be used or designed to be used to cause
vaporization of a controlled substance for inhalation;
   (D) smoking and carburetion masks;
   (E) roach clips, objects used to hold burning material, such as a
marijuana cigarette, that has become too small or too short to be held in
the hand;
   (F) miniature cocaine spoons and cocaine vials;
   (G) chamber smoking pipes;
   (H) carburetor smoking pipes;
   (I) electric smoking pipes;
   (J) air-driven smoking pipes;
   (K) chillums;
   (L) bongs;
   (M) ice pipes or chillers;
any smoking pipe manufactured to disguise its intended purpose;
wired cigarette papers; or
cocaine freebase kits.

"Drug paraphernalia" shall not include any products, chemicals or
materials described in K.S.A. 2018 Supp. 21-5709(a), and amendments
thereto.

"Immediate precursor" means a substance which the state
board of pharmacy has found to be and by rules and regulations designates
as being the principal compound commonly used or produced primarily
for use and which is an immediate chemical intermediary used or
likely to be used in the manufacture of a controlled substance, the control
of which is necessary to prevent, curtail or limit manufacture.

"Isomer" means all enantiomers and diastereomers.

"Manufacture" means the production, preparation, propagation,
compounding, conversion or processing of a controlled substance either
directly or indirectly or by extraction from substances of natural origin or
independently by means of chemical synthesis or by a combination of
extraction and chemical synthesis. "Manufacture" does not include:

(1) The preparation or compounding of a controlled substance by an
individual for the individual's own lawful use or the preparation,
compounding, packaging or labeling of a controlled substance:

(A) By a practitioner or the practitioner's agent pursuant to a lawful
order of a practitioner as an incident to the practitioner's administering or
dispensing of a controlled substance in the course of the practitioner's
professional practice; or

(B) by a practitioner or by the practitioner's authorized agent under
such practitioner's supervision for the purpose of or as an incident to
research, teaching or chemical analysis or by a pharmacist or medical care
facility as an incident to dispensing of a controlled substance; or

(2) the addition of diluents or adulterants, including, but not limited
to, quinine hydrochloride, mannitol, mannite, dextrose or lactose, which
are intended for use in cutting a controlled substance.

"Marijuana" means all parts of all varieties of the plant Cannabis
whether growing or not, the resin extracted from any
part of the plant and every compound, manufacture, salt, derivative,
mixture or preparation of the plant, its seeds or resin. "Marijuana" does not
include: (1) The mature stalks of the plant, fiber produced from the stalks,
oil or cake made from the seeds of the plant, any other compound,
manufacture, salt, derivative, mixture or preparation of the mature stalks,
except the resin extracted therefrom, fiber, oil or cake or the sterilized seed
of the plant which is incapable of germination; (2) any substance
listed in schedules II through V of the uniform controlled substances act;
or (3) cannabidiol (other trade name: 2-[(3-methyl-6-(1-methylethenyl)]-2-
cyclohexen-1-yl]-5-pentyl-1,3-benzenediol); or (4) industrial hemp as
defined in K.S.A. 2018 Supp. 2-3901, and amendments thereto, when
cultivated, produced, possessed or used for activities authorized by the
commercial industrial hemp act.

(k) "Minor" means a person under 18 years of age.

(l) "Narcotic drug" means any of the following whether produced
directly or indirectly by extraction from substances of vegetable origin or
independently by means of chemical synthesis or by a combination of
extraction and chemical synthesis:

(1) Opium and opiate and any salt, compound, derivative or
preparation of opium or opiate;

(2) any salt, compound, isomer, derivative or preparation thereof
which that is chemically equivalent or identical with any of the substances
referred to in paragraph (1) but not including the isoquinoline alkaloids of
opium;

(3) opium poppy and poppy straw;

(4) coca leaves and any salt, compound, derivative or preparation of
coca leaves and any salt, compound, isomer, derivative or preparation
thereof which that is chemically equivalent or identical with any of these
substances, but not including decocainized coca leaves or extractions of
coca leaves which that do not contain cocaine or ecgonine.

(m) "Opiate" means any substance having an addiction-forming or
addiction-sustaining liability similar to morphine or being capable of
conversion into a drug having addiction-forming or addiction-sustaining
liability. "Opiate" does not include, unless specifically designated as
controlled under K.S.A. 65-4102, and amendments thereto, the
dextrotroratory isomer of 3-methoxy-n-methylmorphinan and its salts
(dextromethorphan). "Opiate" does include its racemic and levorotatory
forms.

(n) "Opium poppy" means the plant of the species Papaver
somniferum l. except its seeds.

(o) "Person" means an individual, corporation, government or
governmental subdivision or agency, business trust, estate, trust,
partnership, association or any other legal entity.

(p) "Poppy straw" means all parts, except the seeds, of the opium
poppy, after mowing.

(q) "Possession" means having joint or exclusive control over an item
with knowledge of and intent to have such control or knowingly keeping
some item in a place where the person has some measure of access and
right of control.

(r) "School property" means property upon which is located a
structure used by a unified school district or an accredited nonpublic
school for student instruction or attendance or extracurricular activities of
pupils enrolled in kindergarten or any of the grades one through 12. This
definition shall not be construed as requiring that school be in session or
that classes are actually being held at the time of the offense or that
children must be present within the structure or on the property during the
time of any alleged criminal act. If the structure or property meets the
above definition, the actual use of that structure or property at the time
alleged shall not be a defense to the crime charged or the sentence
imposed.

(s) "Simulated controlled substance" means any product—which that
identifies itself by a common name or slang term associated with a
controlled substance and—which that indicates on its label or accompanying
promotional material that the product simulates the effect of a controlled
substance.

Sec. 11. K.S.A. 2018 Supp. 21-5702 is hereby amended to read as
follows: 21-5702. (a) Prosecutions for crimes committed prior to July 1,
2009, shall be governed by the law in effect at the time the crime was
committed. For purposes of this section, a crime was committed prior to
July 1, 2009, if any element of the crime occurred prior thereto.

(b) The prohibitions of this act shall apply unless the conduct
prohibited is authorized by the pharmacy act of the state of Kansas, the
uniform controlled substances act, the—alternative crop research—
commercial industrial hemp act or otherwise authorized by law.

Sec. 12. K.S.A. 65-4101 is hereby amended to read as follows: 65-
4101. As used in this act: (a) "Administer" means the direct application of
a controlled substance, whether by injection, inhalation, ingestion or any
other means, to the body of a patient or research subject by:

(1) A practitioner or pursuant to the lawful direction of a practitioner;
or

(2) the patient or research subject at the direction and in the presence
of the practitioner.

(b) "Agent" means an authorized person who acts on behalf of or at
the direction of a manufacturer, distributor or dispenser. It does not include
a common carrier, public warehouseman or employee of the carrier or
warehouseman.

(c) "Application service provider" means an entity that sells
electronic prescription or pharmacy prescription applications as a hosted
service where the entity controls access to the application and maintains
the software and records on its server.

(d) "Board" means the state board of pharmacy.

(e) "Bureau" means the bureau of narcotics and dangerous drugs,
United States department of justice, or its successor agency.

(f) "Controlled substance" means any drug, substance or immediate
precursor included in any of the schedules designated in K.S.A. 65-4105,
HB 2167—Am. by SCW


(g) (1) "Controlled substance analog" means a substance that is intended for human consumption, and at least one of the following:
   (A) The chemical structure of the substance is substantially similar to the chemical structure of a controlled substance listed in or added to the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto;
   (B) the substance has a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto; or
   (C) with respect to a particular individual, such individual represents or intends the substance to have a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto.

(2) "Controlled substance analog" does not include:
   (A) A controlled substance;
   (B) a substance for which there is an approved new drug application;
   (C) a substance with respect to which an exemption is in effect for investigational use by a particular person under section 505 of the federal food, drug and cosmetic act, 21 U.S.C. § 355, to the extent conduct with respect to the substance is permitted by the exemption.

(h) "Counterfeit substance" means a controlled substance which, or the container or labeling of which, without authorization bears the trademark, trade name or other identifying mark, imprint, number or device or any likeness thereof of a manufacturer, distributor or dispenser other than the person who in fact manufactured, distributed or dispensed the substance.

(i) "Cultivate" means the planting or promotion of growth of five or more plants which contain or can produce controlled substances.

(j) "DEA" means the U.S. department of justice, drug enforcement administration.

(k) "Deliver" or "delivery" means the actual, constructive or attempted transfer from one person to another of a controlled substance, whether or not there is an agency relationship.

(l) "Dispense" means to deliver a controlled substance to an ultimate user or research subject by or pursuant to the lawful order of a practitioner, including the packaging, labeling or compounding necessary to prepare the substance for that delivery, or pursuant to the prescription of a mid-level


practitioner.

(m) "Dispenser" means a practitioner or pharmacist who dispenses, or a physician assistant who has authority to dispense prescription-only drugs in accordance with K.S.A. 65-28a08(b), and amendments thereto.

(n) "Distribute" means to deliver other than by administering or dispensing a controlled substance.

(o) "Distributor" means a person who distributes.

(p) "Drug" means: (1) Substances recognized as drugs in the official United States pharmacopeia, official homeopathic pharmacopoeia of the United States or official national formulary or any supplement to any of them; (2) substances intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in human or animals; (3) substances (other than food) intended to affect the structure or any function of the body of human or animals; and (4) substances intended for use as a component of any article specified in paragraph (1), (2) or (3). It does not include devices or their components, parts or accessories.

(q) "Immediate precursor" means a substance which the board has found to be and by rule and regulation designates as being the principal compound commonly used or produced primarily for use and which is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail or limit manufacture.

(r) "Electronic prescription" means an electronically prepared prescription that is authorized and transmitted from the prescriber to the pharmacy by means of electronic transmission.

(s) "Electronic prescription application" means software that is used to create electronic prescriptions and that is intended to be installed on the prescriber's computers and servers where access and records are controlled by the prescriber.

(t) "Electronic signature" means a confidential personalized digital key, code, number or other method for secure electronic data transmissions which identifies a particular person as the source of the message, authenticates the signatory of the message and indicates the person's approval of the information contained in the transmission.

(u) "Electronic transmission" means the transmission of an electronic prescription, formatted as an electronic data file, from a prescriber's electronic prescription application to a pharmacy's computer, where the data file is imported into the pharmacy prescription application.

(v) "Electronically prepared prescription" means a prescription that is generated using an electronic prescription application.

(w) "Facsimile transmission" or "fax transmission" means the transmission of a digital image of a prescription from the prescriber or the prescriber's agent to the pharmacy. "Facsimile transmission" includes, but
is not limited to, transmission of a written prescription between the
prescriber's fax machine and the pharmacy's fax machine; transmission of
an electronically prepared prescription from the prescriber's electronic
prescription application to the pharmacy's fax machine, computer or
printer; or transmission of an electronically prepared prescription from the
prescriber's fax machine to the pharmacy's fax machine, computer or
printer.

(x) "Intermediary" means any technology system that receives and
transmits an electronic prescription between the prescriber and the
pharmacy.

(y) "Isomer" means all enantiomers and diastereomers.

(z) "Manufacture" means the production, preparation, propagation,
compounding, conversion or processing of a controlled substance either
directly or indirectly or by extraction from substances of natural origin or
independently by means of chemical synthesis or by a combination of
extraction and chemical synthesis and includes any packaging or
repackaging of the substance or labeling or relabeling of its container,
except that this term does not include the preparation or compounding of a
controlled substance by an individual for the individual's own lawful use
or the preparation, compounding, packaging or labeling of a controlled
substance:

(1) By a practitioner or the practitioner's agent pursuant to a lawful
order of a practitioner as an incident to the practitioner's administering or
dispensing of a controlled substance in the course of the practitioner's
professional practice; or

(2) by a practitioner or by the practitioner's authorized agent under
such practitioner's supervision for the purpose of or as an incident to
research, teaching or chemical analysis or by a pharmacist or medical care
facility as an incident to dispensing of a controlled substance.

(aa) "Marijuana" means all parts of all varieties of the plant Cannabis
whether growing or not, the seeds thereof, the resin extracted from any
part of the plant and every compound, manufacture, salt, derivative,
mixture or preparation of the plant, its seeds or resin. It does not include:
(1) The mature stalks of the plant, fiber produced from the stalks, oil or
cake made from the seeds of the plant, any other compound, manufacture,
salt, derivative, mixture or preparation of the mature stalks, except the
resin extracted therefrom, fiber, oil or cake or the sterilized seed of the
plant which that is incapable of germination; (2) any substance listed in
schedules II through V of the uniform controlled substances act; or (3)
cannabidiol (other trade name: 2-[(3-methyl-6-(1-methylethenyl)-2-
cyclohexen-1-yl]-5-pentyl-1,3-benzenediol); or (4) industrial hemp as
defined in K.S.A. 2018 Supp. 2-3901, and amendments thereto, when
cultivated, produced, possessed or used for activities authorized by the
commercial industrial hemp act.

(bb) "Medical care facility" shall have the meaning ascribed to that term in K.S.A. 65-425, and amendments thereto.

(cc) "Mid-level practitioner" means a certified nurse-midwife engaging in the independent practice of midwifery under the independent practice of midwifery act, an advanced practice registered nurse issued a license pursuant to K.S.A. 65-1131, and amendments thereto, who has authority to prescribe drugs pursuant to a written protocol with a responsible physician under K.S.A. 65-1130, and amendments thereto, or a physician assistant licensed under the physician assistant licensure act who has authority to prescribe drugs pursuant to a written agreement with a supervising physician under K.S.A. 65-28a08, and amendments thereto.

(dd) "Narcotic drug" means any of the following whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis:

(1) Opium and opiate and any salt, compound, derivative or preparation of opium or opiate;
(2) any salt, compound, isomer, derivative or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (1) but not including the isoquinoline alkaloids of opium;
(3) opium poppy and poppy straw;
(4) coca leaves and any salt, compound, derivative or preparation of coca leaves, and any salt, compound, isomer, derivative or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions of coca leaves which do not contain cocaine or ecgonine.

(ee) "Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. It does not include, unless specifically designated as controlled under K.S.A. 65-4102, and amendments thereto, the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). It does include its racemic and levorotatory forms.

(ff) "Opium poppy" means the plant of the species Papaver somniferum l. except its seeds.

(gg) "Person" means an individual, corporation, government, or governmental subdivision or agency, business trust, estate, trust, partnership or association or any other legal entity.

(hh) "Pharmacist" means any natural person licensed under K.S.A. 65-1625 et seq., and amendments thereto, to practice pharmacy.

(ii) "Pharmacist intern" means: (1) A student currently enrolled in an
accredited pharmacy program; (2) a graduate of an accredited pharmacy program serving such person's internship; or (3) a graduate of a pharmacy program located outside of the United States which that is not accredited and who had successfully passed equivalency examinations approved by the board.

(jj) "Pharmacy prescription application" means software that is used to process prescription information, is installed on a pharmacy's computers and servers, and is controlled by the pharmacy.

(kk) "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.

(ll) "Practitioner" means a person licensed to practice medicine and surgery, dentist, podiatrist, veterinarian, optometrist, or scientific investigator or other person authorized by law to use a controlled substance in teaching or chemical analysis or to conduct research with respect to a controlled substance.

(mm) "Prescriber" means a practitioner or a mid-level practitioner.

(nn) "Production" includes the manufacture, planting, cultivation, growing or harvesting of a controlled substance.

(oo) "Readily retrievable" means that records kept by automatic data processing applications or other electronic or mechanized recordkeeping systems can be separated out from all other records within a reasonable time not to exceed 48 hours of a request from the board or other authorized agent or that hard-copy records are kept on which certain items are asterisked, redlined or in some other manner visually identifiable apart from other items appearing on the records.

(pp) "Ultimate user" means a person who lawfully possesses a controlled substance for such person's own use or for the use of a member of such person's household or for administering to an animal owned by such person or by a member of such person's household.

Sec. 13. K.S.A. 65-4105 is hereby amended to read as follows: 65-4105. (a) The controlled substances listed in this section are included in schedule I and the number set forth opposite each drug or substance is the DEA controlled substances code which that has been assigned to it.

(b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

1. Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide). .................................................................9821
2. Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide). ........................................9815
3. Acetylmethadol.................................................................9601
4. Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide;
<table>
<thead>
<tr>
<th></th>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Acryloylfentanyl</td>
<td>9811</td>
</tr>
<tr>
<td>5</td>
<td>AH-7921 (3,4-dichloro-N-[1-(1-dimethylamino)cyclohexylmethyl]benzamide)</td>
<td>9551</td>
</tr>
<tr>
<td>6</td>
<td>Allylprodine</td>
<td>9602</td>
</tr>
<tr>
<td>7</td>
<td>Alphacetylmethadol (except levo-alphacetylmethadol also known as levo-alpha-acetylmethadol, levomethadyl acetate or LAAM)</td>
<td>9603</td>
</tr>
<tr>
<td>8</td>
<td>Alphameprodine</td>
<td>9604</td>
</tr>
<tr>
<td>9</td>
<td>Betameprodine</td>
<td>9605</td>
</tr>
<tr>
<td>10</td>
<td>Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine)</td>
<td>9814</td>
</tr>
<tr>
<td>11</td>
<td>Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide)</td>
<td>9832</td>
</tr>
<tr>
<td>12</td>
<td>Benzethidine</td>
<td>9606</td>
</tr>
<tr>
<td>13</td>
<td>Betacetylmethadol</td>
<td>9607</td>
</tr>
<tr>
<td>14</td>
<td>Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidyl]-N-phenylpropanamide)</td>
<td>9830</td>
</tr>
<tr>
<td>15</td>
<td>Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide)</td>
<td>9831</td>
</tr>
<tr>
<td>16</td>
<td>Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]-piperidin-4-yl]-N-phenylpropionamide)</td>
<td>9836</td>
</tr>
<tr>
<td>17</td>
<td>Betameprodine</td>
<td>9608</td>
</tr>
<tr>
<td>18</td>
<td>Betamethadol</td>
<td>9609</td>
</tr>
<tr>
<td>19</td>
<td>Beta-prodine</td>
<td>9611</td>
</tr>
<tr>
<td>20</td>
<td>Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide)</td>
<td>9822</td>
</tr>
<tr>
<td>21</td>
<td>Clonitazene</td>
<td>9612</td>
</tr>
<tr>
<td>22</td>
<td>Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide)</td>
<td>9845</td>
</tr>
<tr>
<td>23</td>
<td>Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide)</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Dextromoramide</td>
<td>9613</td>
</tr>
<tr>
<td>25</td>
<td>Diampromide</td>
<td>9615</td>
</tr>
<tr>
<td>26</td>
<td>Diethylthiambutene</td>
<td>9616</td>
</tr>
<tr>
<td>27</td>
<td>Difenoxin</td>
<td>9168</td>
</tr>
<tr>
<td>28</td>
<td>Dimenoxadol</td>
<td>9617</td>
</tr>
<tr>
<td>29</td>
<td>Dimepheptanol</td>
<td>9618</td>
</tr>
<tr>
<td>30</td>
<td>Dimethylthiambutene</td>
<td>9619</td>
</tr>
<tr>
<td>31</td>
<td>Oxaphetyl butyrate</td>
<td>9621</td>
</tr>
<tr>
<td>32</td>
<td>Dipipanone</td>
<td>9622</td>
</tr>
<tr>
<td>33</td>
<td>Ethylmethylthiambutene</td>
<td>9623</td>
</tr>
<tr>
<td>34</td>
<td>Etonitazene</td>
<td>9624</td>
</tr>
<tr>
<td>No.</td>
<td>Name</td>
<td>CAS Number</td>
</tr>
<tr>
<td>-----</td>
<td>----------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>1</td>
<td>Etoxeridine</td>
<td>9625</td>
</tr>
<tr>
<td>2</td>
<td>Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-</td>
<td>9834</td>
</tr>
<tr>
<td></td>
<td>carboxamide)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Furethidine</td>
<td>9626</td>
</tr>
<tr>
<td>4</td>
<td>Hydroxypethidine</td>
<td>9627</td>
</tr>
<tr>
<td>5</td>
<td>Isobutryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide)</td>
<td>9626</td>
</tr>
<tr>
<td>6</td>
<td>Ketobemidone</td>
<td>9628</td>
</tr>
<tr>
<td>7</td>
<td>Levomoramide</td>
<td>9629</td>
</tr>
<tr>
<td>8</td>
<td>Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-</td>
<td>9825</td>
</tr>
<tr>
<td></td>
<td>phenylacetamid)</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide)</td>
<td>9813</td>
</tr>
<tr>
<td>10</td>
<td>3-Methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-</td>
<td>9833</td>
</tr>
<tr>
<td></td>
<td>phenylpropanamide)</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Morpheridine</td>
<td>9632</td>
</tr>
<tr>
<td>12</td>
<td>Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-</td>
<td>9816</td>
</tr>
<tr>
<td></td>
<td>yl)acetamid)</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>O-desmethyltramadol</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Some trade or other names: 2-((dimethylamino)methyl-1-(3-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>hydroxyphenyl)cyclohexanol;3-(2-((dimethylamino)methyl)-1-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>hydroxyxycyclohexyl)phenol</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>MPPP (1-methyl-4-phenyl-4-propionoxypiperidine)</td>
<td>9661</td>
</tr>
<tr>
<td>16</td>
<td>MT-45 (1-cychohexyl-4-(1,2-diphenylethyl)piperazine)</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Noracymethadol</td>
<td>9633</td>
</tr>
<tr>
<td>18</td>
<td>Norlevorphanol</td>
<td>9634</td>
</tr>
<tr>
<td>19</td>
<td>Normethadone</td>
<td>9635</td>
</tr>
<tr>
<td>20</td>
<td>Norpipanone</td>
<td>9636</td>
</tr>
<tr>
<td>21</td>
<td>Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)</td>
<td>9816</td>
</tr>
<tr>
<td></td>
<td>propionamide; 2-fluorofentanylyl)</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Para-chloroisobutryl fentanyl (N-(4-chlorophenyl)-N-(1-phenethylpip</td>
<td>9812</td>
</tr>
<tr>
<td></td>
<td>eridin-4-yl)isobutryramide</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Para-fluorobutryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-</td>
<td>9824</td>
</tr>
<tr>
<td></td>
<td>4-yl)butryramide</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Para-flurofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]propanamide)</td>
<td>9812</td>
</tr>
<tr>
<td>25</td>
<td>Para-fluroisobutryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpip</td>
<td>9824</td>
</tr>
<tr>
<td></td>
<td>eridin-4-yl)isobutryramide</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Para-methoxybutryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpip</td>
<td>9824</td>
</tr>
<tr>
<td></td>
<td>eridin-4-yl)butryramide</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine)</td>
<td>9663</td>
</tr>
</tbody>
</table>
(62) Phenadoxone.................................................................9637
(63) Phenampromide.........................................................9638
(64) Phenomorphan............................................................9647
(65) Phenoperidine.............................................................9641
(66) Piritramide.................................................................9642
(67) Proheptazine...............................................................9643
(68) Properidine.................................................................9644
(69) Propiram......................................................................9649
(70) Racemoramide.............................................................9645
(71) Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
phenyltetrahydrofuran-2-carboxamide)..................................9843
(72) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-
propanamide).......................................................................9835
(73) Tilidine...........................................................................9750
(74) Trimeperidine...............................................................9646
(75) U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
methylbenzamide).................................................................9547
(76) Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
phenylpentanamide)

(c) Any of the following opium derivatives, their salts, isomers and
salts of isomers, unless specifically excepted, whenever the existence of
these salts, isomers and salts of isomers is possible within the specific
chemical designation:

(1) Acetorphine......................................................................9319
(2) Acetyldihydrocodeine.......................................................9051
(3) Benzylmorphine..............................................................9052
(4) Codeine methylbromide.....................................................9070
(5) Codeine-N-Oxide.............................................................9053
(6) Cyprenorphine...............................................................9054
(7) Desomorphine..................................................................9055
(8) Dihydromorphine............................................................9145
(9) Drotebanol.......................................................................9335
(10) Etorphine (except hydrochloride salt)...............................9056
(11) Heroin.........................................................................9200
(12) Hydromorphinol............................................................9301
(13) Methyldesorphine..........................................................9302
(14) Methyldihydromorphine..................................................9304
(15) Morphine methylbromide.................................................9305
(16) Morphine methylsulfonate...............................................9306
(17) Morphine-N-Oxide........................................................9307
(18) Myrophine......................................................................9308
(19) Nicocodeine....................................................................9309
(20) Nicomorphine...............................................................9312
(21) Normorphine..........................................................................................9313
(22) Pholcodine.............................................................................................9314
(23) Thebacon..................................................................................................9315

(d) Any material, compound, mixture or preparation—which that
contains any quantity of the following hallucinogenic substances, their
salts, isomers and salts of isomers, unless specifically excepted, whenever
the existence of these salts, isomers and salts of isomers is possible within
the specific chemical designation:

(1) Alpha-ethyltryptamine 7249 Some trade or other names:
etryptamine; Monase; α-ethyl-1H-indole-3-ethanamine; 3-(2-
aminobutyl) indole; α-ET; and AET.
(2) 4-bromo-2,5-dimethoxy-amphetamine.................................7391
Some trade or other names: 4-bromo-2,5-dimethoxy-alpha-
 methylphenethylamine; 4-bromo-2,5-DMA.
(3) 2,5-dimethoxyamphetamine.........................................................7396
Some trade or other names: 2,5-dimethoxy-alpha-methyl-
 phenethylamine; 2,5-DMA.
(4) 4-methoxyamphetamine.................................................................7411
Some trade or other names: 4-methoxy-alpha-methylphene-
 thylamine; paramethoxyamphetamine; PMA.
(5) 5-methoxy-3,4-methylenedioxy-amphetamine......................7401
(6) 4-methyl-2,5-dimethoxy-amphetamine.................................7395
Some trade or other names: 4-methyl-2,5-dimethoxy-alpha-
 methylphenethylamine; "DOM"; and "STP".
(7) 3,4-methylenedioxy amphetamine............................................7400
(8) 3,4-methylenedioxymethamphetamine (MDMA).....................7405
(9) 3,4-methylenedioxy-N-ethylamphetamine (also known as N-ethyl-
 alpha-methyl-3,4 (methylenedioxy) phenethylamine, N-ethyl MDA,
 MDE, and MDEA). .................................................................7404
(10) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-
 hydroxy-alpha-methyl-3,4-(methylenedioxy) phenethylamine, and
 N-hydroxy MDA)... .................................................................7402
(11) 3,4,5-trimethoxy amphetamine....................................................7390
(12) Bufotenine..........................................................................................7433
Some trade or other names: 3-(Beta-Dimethylaminoethyl)-5-
 hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N, N-
dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine.
(13) Diethyltryptamine.............................................................................7434
Some trade or other names: N,N-Diethyltryptamine; DET.
(14) Dimethyltryptamine.........................................................................7435
Some trade or other names: DMT.
(15) Ibogaine.............................................................................................7260
Some trade or other names: 7-Ethyl-6,6 Beta,7,8,9,10,12,13-
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>octahydro-2-methoxy-6,9-methano-5H-pyrido[1',2':1,2] azepino</td>
</tr>
<tr>
<td>2</td>
<td>[5,4-b]indole; Tabernanthe iboga</td>
</tr>
<tr>
<td>3</td>
<td>(16) Lysergic acid diethylamide...............................................................7315</td>
</tr>
<tr>
<td>4</td>
<td>(17) Marijuana............................................................................................7360</td>
</tr>
<tr>
<td>5</td>
<td>(18) Mescaline................................................................................................7381</td>
</tr>
<tr>
<td>6</td>
<td>(19) Parahexyl................................................................................................7374</td>
</tr>
<tr>
<td>7</td>
<td>Some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl.</td>
</tr>
<tr>
<td>8</td>
<td>(20) Peyote ...................................................................................................7415</td>
</tr>
<tr>
<td>9</td>
<td>Meaning all parts of the plant presently classified botanically as Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture or preparation of such plant, its seeds or extracts.</td>
</tr>
<tr>
<td>10</td>
<td>(21) N-ethyl-3-piperidyl benzilate...............................................................7482</td>
</tr>
<tr>
<td>11</td>
<td>(22) N-methyl-3-piperidyl benzilate.............................................................7484</td>
</tr>
<tr>
<td>12</td>
<td>(23) Psilocybin...............................................................................................7437</td>
</tr>
<tr>
<td>13</td>
<td>(24) Psilocyn....................................................................................................7438</td>
</tr>
<tr>
<td>14</td>
<td>Some trade or other names: Psilocin.</td>
</tr>
<tr>
<td>15</td>
<td>(25) Ethylamine analog of phencyclidine......................................................7455</td>
</tr>
<tr>
<td>16</td>
<td>Some trade or other names: N-ethyl-1-phenyl-cyclo-hexylamine; (1-phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine; cyclohexamine; PCE.</td>
</tr>
<tr>
<td>17</td>
<td>(26) Pyrrolidine analog of phencyclidine......................................................7458</td>
</tr>
<tr>
<td>18</td>
<td>Some trade or other names: 1-(1-phenylcyclohexyl)-pyrrolidine; PCPP; PHP.</td>
</tr>
<tr>
<td>19</td>
<td>(27) Thiophene analog of phencyclidine.........................................................7470</td>
</tr>
<tr>
<td>20</td>
<td>Some trade or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine; 2-thiényl analog of phencyclidine; TCPP; TCP.</td>
</tr>
<tr>
<td>21</td>
<td>(28) 1-[1-(2-thienyl)-cyclohexyl] pyrrolidine................................................7473</td>
</tr>
<tr>
<td>22</td>
<td>Some other names: TCPy.</td>
</tr>
<tr>
<td>23</td>
<td>(29) 2,5-dimethoxy-4-ethylamphetamine......................................................7399</td>
</tr>
<tr>
<td>24</td>
<td>Some trade or other names: DOET.</td>
</tr>
<tr>
<td>25</td>
<td>(30) Salvia divinorum or salvinorum A; all parts of the plant presently classified botanically as salvia divinorum, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture or preparation of such plant, its seeds or extracts.</td>
</tr>
<tr>
<td>26</td>
<td>(31) Datura stramonium, commonly known as gypsum weed or jimson weed; all parts of the plant presently classified botanically as datura stramonium, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture or preparation of such plant, its seeds or extracts.</td>
</tr>
<tr>
<td>No.</td>
<td>Substance</td>
</tr>
<tr>
<td>-----</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>32</td>
<td>N-benzylpiperazine</td>
</tr>
<tr>
<td>33</td>
<td>1-(3-[trifluoromethylphenyl])piperazine</td>
</tr>
<tr>
<td>34</td>
<td>4-Bromo-2,5-dimethoxyphenethylamine</td>
</tr>
<tr>
<td>35</td>
<td>2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts and salts of optical isomers</td>
</tr>
<tr>
<td>36</td>
<td>Alpha-methyltryptamine (other name: AMT)</td>
</tr>
<tr>
<td>37</td>
<td>5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its isomers, salts and salts of isomers</td>
</tr>
<tr>
<td>38</td>
<td>2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)</td>
</tr>
<tr>
<td>39</td>
<td>2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)</td>
</tr>
<tr>
<td>40</td>
<td>2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)</td>
</tr>
<tr>
<td>41</td>
<td>2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)</td>
</tr>
<tr>
<td>42</td>
<td>2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)</td>
</tr>
<tr>
<td>43</td>
<td>2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)</td>
</tr>
<tr>
<td>44</td>
<td>2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)</td>
</tr>
<tr>
<td>45</td>
<td>2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine (2C-N)</td>
</tr>
<tr>
<td>46</td>
<td>2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)</td>
</tr>
<tr>
<td>47</td>
<td>5-methoxy-N,N-dimethyltryptamine (5-MeO–DMT)</td>
</tr>
<tr>
<td>48</td>
<td>2-(4-Iodo–2,5–dimethoxyphenyl)–N–(2–methoxybenzyl)</td>
</tr>
<tr>
<td>49</td>
<td>2–(4–chloro–2,5–dimethoxyphenyl)–N–(2–methoxybenzyl)</td>
</tr>
<tr>
<td>50</td>
<td>2–(4–bromo–2,5–dimethoxyphenyl)–N–(2–methoxybenzyl)</td>
</tr>
<tr>
<td>51</td>
<td>2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine</td>
</tr>
<tr>
<td>52</td>
<td>2-(2,5-dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine</td>
</tr>
<tr>
<td>53</td>
<td>2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl)ethanamine</td>
</tr>
<tr>
<td>54</td>
<td>Any material, compound, mixture or preparation— which that contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts</td>
</tr>
</tbody>
</table>

(e) Any material, compound, mixture or preparation which that contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts.
of isomers whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation:

(1) Etizolam
Some trade or other names: (4-(2-chlorophenyl)-2-ethyl-9-methyl-
6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine)

(2) Mecloqualone..........................................................2572

(3) Methaqualone..........................................................2565

(4) Gamma hydroxybutyric acid

(f) Unless specifically excepted or unless listed in another schedule,
any material, compound, mixture or preparation—which that contains any
quantity of the following substances having a stimulant effect on the
central nervous system, including its salts, isomers and salts of isomers:

(1) Aminorex...............................................................1585
Some other names: Aminoxaphen 2-amino-5-phenyl-2-oxazoline or
4,5-dihydro-5-phenyl-2-oxazolamine

(2) Fenethylline............................................................1503

(3) N-ethylamphetamine...............................................1475

(4) (+)-cis-4-methyaminorex ((+)-cis-4,5-dihydro-4-methyl-5-phenyl-2-
oxazolamine).........................................................1590

(5) N,N-dimethylnaphthylethanolamine (also known as N,N-alpha-trimethyl-
benzenecethanamine; N,N-alpha-trimethylphenethylamine)........1480

(6) Cathinone (some other names: 2-amino-1-phenol-1-propanone,
alpha-amino propiophenone, 2-amino propiophenone and
norphedrone).............................................................1235

(7) Substituted cathinones
Any compound, except bupropion or compounds listed under a
different schedule, structurally derived from 2–aminopropan–1–one
by substitution at the 1-position with either phenyl, naphthyl, or
thiophene ring systems, whether or not the compound is further
modified in any of the following ways:

(A) By substitution in the ring system to any extent with alkyl,
alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide
substituents, whether or not further substituted in the ring
system by one or more other univalent substituents;

(B) by substitution at the 3-position with an acyclic alkyl
substituent;

(C) by substitution at the 2-amino nitrogen atom with alkyl,
dialkyl, benzyl, or methoxybenzyl groups; or

(D) by inclusion of the 2-amino nitrogen atom in a cyclic
structure.

(g) Any material, compound, mixture or preparation—which that
contains any quantity of the following substances:

(1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its
optical isomers, salts and salts of isomers

(2) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide
(thenylfentanyl), its optical isomers, salts and salts of isomers

(h) Any of the following cannabinoids, their salts, isomers and salts
of isomers, unless specifically excepted, whenever the existence of these
salts, isomers and salts of isomers is possible within the specific chemical
designation:

(1) Tetrahydrocannabinols.................................................................7370
Meaning tetrahydrocannabinols naturally contained in a plant of the
genus Cannabis (cannabis plant), as well as synthetic equivalents of
the substances contained in the plant, or in the resinous extractives of
Cannabis, sp. and/or synthetic substances, derivatives, and their
isomers with similar chemical structure and pharmacological activity
such as the following: Delta 1 cis or trans tetrahydrocannabinol, and
their optical isomers Delta 6 cis or trans tetrahydrocannabinol, and
their optical isomers Delta 3,4 cis or trans tetrahydrocannabinol, and
its optical isomers (Since nomenclature of these substances is not
internationally standardized, compounds of these structures,
regardless of numerical designation of atomic positions covered.),
except tetrahydrocannabinols in any of the following:

(A) Industrial hemp, as defined in K.S.A. 2018 Supp. 2-3901, and
amendments thereto;

(B) solid waste, as defined in K.S.A. 65-3402, and amendments
thereto, and hazardous waste, as defined in K.S.A. 65-3430,
and amendments thereto, if such waste is the result of the
cultivation, production or processing of industrial hemp, as
defined in K.S.A. 2018 Supp. 2-3901, and amendments
thereto, and such waste contains a delta-9
tetrahydrocannabinol concentration of not more than 0.3% on
a dry weight basis; or

(C) hemp products, as defined in K.S.A. 2018 Supp. 2-3901, and
amendments thereto, unless otherwise deemed unlawful
pursuant to section 5, and amendments thereto.

(2) Naphthoylindoles
Any compound containing a 3-(1-naphthoyl)indole structure with
substitution at the nitrogen atom of the indole ring by an alkyl,
haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl) ethyl
group, whether or not further substituted in the indole ring to any
extent and whether or not substituted in the benzyl or naphthyl ring
to any extent.

(3) Naphthylmethylindoles
Any compound containing a 1H-indol-3-yl-(1-naphthyl)methane
structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the benzyl or naphthyl ring to any extent.

(4) Naphthoylpyrroles
Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the benzyl or naphthyl ring to any extent.

(5) Naphthylmethylindenes
Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any extent, whether or not substituted in the benzyl or naphthyl ring to any extent.

(6) Phenylacetylindoles
Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent, whether or not substituted in the benzyl or phenyl ring to any extent.

(7) Cyclohexylphenols
Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted in the cyclohexyl ring to any extent.

(8) Benzylindoles
Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent.
extent and whether or not substituted in the benzyl or phenyl ring to
any extent.

(9) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
1,4-benzoxazin-6-yl]-1-napthalenylmethanone.
Some trade or other names: WIN 55,212-2.

(10) 9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-
6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
Some trade or other names: HU-210, HU-211.

(11) Tetramethylcyclopropanoylindoles
Any compound containing a 3-tetramethylcyclopropanoylindole
structure with substitution at the nitrogen atom of the indole ring by
an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-
3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or
not further substituted in the indole ring to any extent and whether or
not substituted in the benzyl or tetramethylcyclopropyl rings to any
extent.

(12) Indole-3-carboxylate esters
Any compound containing a 1H-indole-3-carboxylate ester structure
with the ester oxygen bearing a naphthyl, quinolinyl, isoquinolinyl or
adamantyl group and substitution at the 1 position of the indole ring
by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
cycloalkylethyl, benzyl, N-methyl-2-piperidinylmethyl or 2-(4-
morpholinyl)ethyl group, whether or not further substituted on the
indole ring to any extent and whether or not substituted on the
naphthyl, quinolinyl, isoquinolinyl, adamantyl or benzyl groups to
any extent.

(13) Indazole-3-carboxamides
Any compound containing a 1H-indazole-3-carboxamide structure
with substitution at the nitrogen of the carboxamide by a naphthyl,
quinolinyl, isoquinolinyl, adamantyl, benzyl, 1-amino-1-oxoalkan-2-
yl or 1-alkoxy-1-oxoalkan-2-yl group and substitution at the 1
position of the indazole ring by an alkyl, haloalkyl, cyanoalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, N-methyl-2-
piperidinylmethyl, or 2-(4-morpholinyl)ethyl group, whether or not
further substituted on the indazole ring to any extent and whether or
not substituted on the naphthyl, quinolinyl, isoquinolinyl, adamantyl,
1-amino-1-oxoalkan-2-yl, 1-alkoxy-1-oxoalkan-2-yl or benzyl
groups to any extent.

(14) Indole-3-carboxamides
Any compound containing a 1H-indole-3-carboxamide structure with
substitution at the nitrogen of the carboxamide by a naphthyl,
quinolinyl, isoquinolinyl, adamantyl, benzyl, 1-amino-1-oxoalkan-2-yl or 1-alkoxy-1-oxoalkan-2-yl group and substitution at the 1 position of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, N-methyl-2-piperidinylmethyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted on the indole ring to any extent and whether or not further substituted on the naphthyl, quinolinyl, isoquinolinyl, adamantyl, 1-amino-1-oxoalkan-2-yl, 1-alkoxy-1-oxoalkan-2-yl or benzyl groups to any extent.

(15) (1H-indazol-3-yl)methanones

Any compound containing a (1H-indazol-3-yl)methanone structure with the carbonyl carbon bearing a naphthyl group and substitution at the 1 position of the indazole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, N-methyl-2-piperidinylmethyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted on the indazole ring to any extent and whether or not substituted on the naphthyl or benzyl groups to any extent.


Sec. 15. On and after July 1, 2019, K.S.A. 2018 Supp. 2-3902 is hereby repealed.

Sec. 16. This act shall take effect and be in force from and after its publication in the Kansas register.